prohibited substance comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-04. Numbers and descriptions here follow the published literature rather than marketing material.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
The physiological role for responses to these, and several other glycoprotein hormones, is not fully understood, although it is likely that ACTH is bifunctional, like PTH, supporting bone formation with periodic spikes of ACTH, but causing bone destruction in large concentrations. In mice, mutations that reduce the efficiency of ACTH-induced glucocorticoid production in the adrenals cause the skeleton to become dense (osteosclerotic bone).
Curium pnictides show ferromagnetic transitions upon cooling: 244CmN and 244CmAs at 109 K, 248CmP at 73 K and 248CmSb at 162 K. The lanthanide analog of curium, gadolinium, and its pnictides, also show magnetic transitions upon cooling, but the transition character is somewhat different: Gd and GdN become ferromagnetic, and GdP, GdAs and GdSb show antiferromagnetic ordering. In accordance with magnetic data, electrical resistivity of curium increases with temperature – about twice between 4 and 60 K – and then is nearly constant up to room temperature. There is a significant increase in resistivity over time (~10 μΩ·cm/h) due to self-damage of the crystal lattice by alpha decay. This makes uncertain the true resistivity of curium (~125 μΩ·cm). Curium's resistivity is similar to that of gadolinium, and the actinides plutonium and neptunium, but significantly higher than that of americium, uranium, polonium and thorium. Under ultraviolet illumination, curium(III) ions show strong and stable yellow-orange fluorescence with a maximum in the range of 590–640 nm depending on their environment. The fluorescence originates from the transitions from the first excited state 6D7/2 and the ground state 8S7/2. Analysis of this fluorescence allows monitoring interactions between Cm(III) ions in organic and inorganic complexes.
AlphaFold 2 (2021) demonstrated the ability to approximate, in hours rather than months, the 3D structure of a protein. In 2023, it was reported that AI-guided drug discovery helped find a class of antibiotics capable of killing two different types of drug-resistant bacteria. In 2024, researchers used machine learning to accelerate the search for Parkinson's disease drug treatments. Their aim was to identify compounds that block the clumping, or aggregation, of alpha-synuclein (the protein that characterises Parkinson's disease). They were able to speed up the initial screening process ten-fold and reduce the cost by a thousand-fold. A 2026 Nature article titled "Dozens of AI disease-prediction models were trained on dubious data" highlighted the use of unreliable data being used to train AI medical prediction models for stroke and diabetes in 125 research articles. Evidence suggested some of the AI tools that were developed on unreliable data had been used on patients, although it was not clear if there were adverse outcomes.
Hitler gave a speech in Berlin on 26 September 1938 and declared that the Sudetenland was "the last territorial demand I have to make in Europe". He also stated that he had told Chamberlain, "I have assured him further that, and this I repeat here before you, once this issue has been resolved, there will no longer be any further territorial problems for Germany in Europe!" On 28 September, Chamberlain appealed to Hitler for a conference. Hitler met the next day at Munich with the chiefs of governments of France, Italy and Britain. The Czechoslovak government was neither invited nor consulted. On 29 September, the Munich Agreement was signed by Germany, Italy, France and Britain. The Czechoslovak government capitulated on 30 September, despite the army's opposition, and agreed to abide by the agreement, which stipulated that Czechoslovakia must cede Sudetenland to Germany. The German occupation of the Sudetenland would be completed by 10 October. An international commission representing Germany, Britain, France, Italy and Czechoslovakia would supervise a plebiscite to determine the final frontier. Britain and France promised to join in an international guarantee of the new frontiers against unprovoked aggression. Germany and Italy, however, would not join in the guarantee until the Polish and Hungarian minority problems were settled. On 5 October 1938, Beneš resigned as president since he realised that the fall of Czechoslovakia was a fait accompli. After the outbreak of World War II, he would form a Czechoslovak government-in-exile in London.
The solubility of calcium sulfate decreases as temperature increases. This behaviour ("retrograde solubility") is uncommon: dissolution of most of the salts is endothermic and their solubility increases with temperature. The retrograde solubility of calcium sulfate is also responsible for its precipitation in the hottest zone of heating systems and for its contribution to the formation of scale in boilers along with the precipitation of calcium carbonate whose solubility also decreases when CO2 degasses from hot water or can escape out of the system.
Sources: en.wikipedia.org
In November 1949, Pauling, Harvey Itano, S. J. Singer and Ibert Wells published "Sickle Cell Anemia, a Molecular Disease" in the journal Science. It was the first proof of a human disease being caused by an abnormal protein, and sickle cell anemia became the first disease understood at the molecular level. (It was not, however, the first demonstration that variant forms of hemoglobin could be distinguished by electrophoresis, which had been shown several years earlier by Maud Menten and collaborators). Using electrophoresis, they demonstrated that individuals with sickle cell disease have a modified form of hemoglobin in their red blood cells, and that individuals with sickle cell trait have both the normal and abnormal forms of hemoglobin. This was the first demonstration causally linking an abnormal protein to a disease, and also the first demonstration that Mendelian inheritance determines the specific physical properties of proteins, not simply their presence or absence – the dawn of molecular genetics. His success with sickle cell anemia led Pauling to speculate that a number of other diseases, including mental illnesses such as schizophrenia, might result from flawed genetics. As chairman of the Division of Chemistry and Chemical Engineering and director of the Gates and Crellin Chemical Laboratories, he encouraged the hiring of researchers with a chemical-biomedical approach to mental illness, a direction not always popular with established Caltech chemists. In 1951, Pauling gave a lecture entitled "Molecular Medicine".
=== Temporal lobe epilepsy === Slow waves, including delta waves, are associated with seizure-like activity within the brain. W. Grey Walter was the first person to use delta waves from an EEG to locate brain tumors and lesions causing temporal lobe epilepsy. Neurofeedback has been suggested as a treatment for temporal lobe epilepsy, and theoretically acts to reduce inappropriate delta wave intrusion, although there has been limited clinical research in this area.
== Inhibitors == There are two types of inhibitor of PPO, those competitive to oxygen in the copper site of the enzyme and those competitive to phenolics. Tentoxin has also been used in recent research to eliminate the PPO activity from seedlings of higher plants. Tropolone is a grape polyphenol oxidase inhibitor. Another inhibitor of this enzyme is potassium metabisulfite. Banana root PPO activity is strongly inhibited by dithiothreitol and sodium metabisulfite, as is banana fruit PPO by similar sulfur-containing compounds including sodium dithionite and cysteine, in addition to ascorbic acid (vitamin C).
=== Sources === This article incorporates text from a free content work. Licensed under CC BY 4.0 (license statement/permission). Text taken from The State of Food Security and Nutrition in the World 2025, Food and Agriculture Organization of the United Nations. This article incorporates text from a free content work. Licensed under CC BY-SA 4.0 (license statement/permission). Text taken from The State of Food Security and Nutrition in the World 2024, Food and Agriculture Organization.
Sources: en.wikipedia.org
== Function == The MAPEG family (Membrane-Associated Proteins in Eicosanoid and Glutathione metabolism) consists of six human proteins, two of which are involved in the production of leukotrienes and prostaglandin E, important mediators of inflammation. Other family members, demonstrating glutathione S-transferase and peroxidase activities, are involved in cellular defense against toxic, carcinogenic, and pharmacologically active electrophilic compounds. This gene encodes a protein that catalyzes the conjugation of glutathione to electrophiles and the reduction of lipid hydroperoxides. This protein is localized to the endoplasmic reticulum and outer mitochondrial membrane where it is thought to protect these membranes from oxidative stress. Four transcript variants of this gene encode one protein isoform.
For example, lung resistance-related proteins, otherwise referred to as major vault proteins, are located on the nuclear membrane of cells and typically mediate nucleocytoplasmic transport. Here, the regulation of compounds between the nucleus and cytoplasm is a process that can be overexpressed by cancer cells to transport DNA-targeted chemotherapeutic drugs away from the nucleus, and essentially restrict these drugs from successfully interacting with their targets. Without reducing the total intracellular chemotherapeutic drug concentration, cancer cells have developed mechanisms to successfully dismantle drug-target interactions and confer resistance to multiple chemotherapeutic drugs. An additional mechanism of resistance interfering with drug-target interaction can be demonstrated by mutations in genes that encode for drug target proteins, such as tubulin. Broadly, tubulin proteins make up intracellular structures known as microtubules that play a fundamental role in cellular shape, division, signaling, and movement, thus making them a particular promising site of target for chemotherapeutic drugs. By altering or inhibiting microtubule dynamics in cancer cells, drugs can prohibit successfully cell division and induce the direct activation of adoptotic pathways. However, mutations that produce physical alterations in tubulin protein structure, can interfere with the several tubulin binding sites and inhibit the effective interaction and activity of these chemotherapeutic drugs.
== External links == Nobel Prize in Physics 1989 The High-precision Penning Trap Mass Spectrometer SMILETRAP in Stockholm, Sweden High-precision mass determination of unstable nuclei with a Penning trap mass spectrometer at ISOLDE/CERN, Switzerland High-precision mass measurements of rare isotopes using the LEBIT and SIPT Penning traps at the National Superconducting Cyclotron Laboratory, USA High-precision mass measurements of short-lived isotopes using the TITAN Penning trap at TRIUMF in Vancouver, Canada
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
Divide it into single-use aliquots and hold them frozen at -20 °C or below, protected from light. Repeated thawing of one container is the main avoidable source of variability.